# Heather Kay Lauren — Lab Results

**Collected:** June 22, 2026 at 3:45 PM  
**Status:** Not yet reviewed by care team  
**Patient:** Heather Kay Lauren  
**Diagnosis:** Stage 4 Gastric Adenocarcinoma (liver/brain mets)  
**Pathology:** pMMR/MSS, HER2 3+

---

## CBC Differential

| Test | Result | Normal Range | Status |
|---|---|---|---|
| Neutrophils Absolute | *(chart)* | 1.5–7.7 K/uL | — |
| Lymphocytes Absolute | *(chart)* | 0.8–5.0 K/uL | — |
| Monocytes Absolute | *(chart)* | 0.1–1.1 K/uL | — |
| Eosinophils Absolute | *(chart)* | ≤0.5 K/uL | — |
| Basophils Absolute | *(chart)* | ≤0.2 K/uL | — |

## CBC Main

| Test | Result | Normal Range | Status |
|---|---|---|---|
| WBC | *(chart)* | 4.0–11.0 K/uL | — |
| RBC | *(chart)* | 3.90–5.20 Million/uL | — |
| Hemoglobin | *(chart)* | 12.0–16.0 g/dL | — |
| Hematocrit | *(chart)* | 36.0–47.0 % | — |
| MCV | *(chart)* | 80.0–99.0 fL | — |

## RBC Indices & Platelets

| Test | Result | Normal Range | Status |
|---|---|---|---|
| MCH | *(chart)* | 27.0–33.0 pg | — |
| MCHC | *(chart)* | 32.0–35.5 g/dL | — |
| **RDW** | **19.7%** | 11.0–15.0 % | ⬆ HIGH |
| Platelet Count | *(chart)* | 135–400 K/uL | — |
| Immature Platelet Fraction | *(chart)* | 1.0–7.0 % | — |

## Coagulation

| Test | Result | Normal Range | Status |
|---|---|---|---|
| **D-Dimer HS** | **6,279 ng/mL FEU** | ≤500 | ⬆⬆ EXTREMELY HIGH |
| PT | *(chart)* | 9.4–12.5 sec | — |
| INR | *(chart)* | 0.9–1.1 | — |
| PTT | *(chart)* | 25.1–36.5 sec | — |
| *Note:* APTT 62.1–100.8 sec = 0.3–0.7 U/mL Heparin for UFH patients | | | |

## Liver Function

| Test | Result | Normal Range | Status |
|---|---|---|---|
| **Alkaline Phosphatase** | **1,443 U/L** | 34–104 | ⬆⬆ 14x NORMAL |
| **ALT (SGPT)** | **46 U/L** | 7–25 | ⬆ HIGH |
| AST (SGOT) | *(chart)* | 13–39 U/L | — |
| Bilirubin, Total | 0.29 mg/dL | 0.20–1.10 | ✓ NORMAL |
| Globulin | *(chart)* | 2.0–4.8 gm/dL | — |
| Albumin/Globulin Ratio | *(chart)* | 0.8–2.2 | — |

## Tumor Markers / Tissue Turnover

| Test | Result | Normal Range | Status |
|---|---|---|---|
| **LDH, Total Serum** | **422 U/L** | 140–271 | ⬆ HIGH |
| **Haptoglobin** | *(chart)* | 30–200 mg/dL | — |

## Comprehensive Metabolic Panel

| Test | Result | Normal Range | Status |
|---|---|---|---|
| **Sodium** | **133 mmol/L** | 136–145 | ⬆ LOW |
| Potassium | *(chart)* | 3.5–5.1 mmol/L | — |
| Chloride | *(chart)* | 98–107 mmol/L | — |
| Carbon Dioxide | *(chart)* | 21.0–32.0 mmol/L | — |
| Anion Gap | *(chart)* | 3–13 | — |
| Calcium | *(chart)* | 8.6–10.3 mg/dL | — |
| BUN | *(chart)* | 7–25 mg/dL | — |
| Creatinine | *(chart)* | 0.600–1.100 mg/dL | — |
| eGFR | 141.9 | >60 mL/min/1.73m² | ✓ NORMAL |
| Total Protein | *(chart)* | 6.4–8.9 g/dL | — |
| Albumin | *(chart)* | 3.5–5.7 g/dL | — |

---

## Key Findings Summary

1. **D-Dimer 6,279** — Massive elevation. Active thrombosis/inflammation cascade. High VTE risk (DVT/PE). Consistent with advanced malignancy.
2. **Alkaline Phosphatase 1,443** — 14x normal. Biliary obstruction or extensive liver/bone involvement. Consistent with liver metastasis burden.
3. **LDH 422** — Elevated tissue turnover. Consistent with tumor burden.
4. **ALT 46** — Mild-moderate hepatocyte injury.
5. **RDW 19.7%** — Significant red cell size variation. Anemia of chronic disease, nutritional deficiency.
6. **Sodium 133** — Mild hyponatremia. Common in advanced illness.
7. **Bilirubin normal (0.29)** — No overt biliary obstruction yet despite massive Alk Phos.
8. **eGFR 141.9** — Kidney function preserved.